Trial
NCT01110226
Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University of Maryland, Baltimore
Collaborators
University of Maryland, College Park
Condition
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Intervention
KML-001
Why stopped
Toxicity was not felt to be acceptable for further development.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-17